Epigenetic modulators as targets in recurrent glioblastoma

Glioblastoma (GBM) is the most common brain cancer in adults. Despite undergoing extensive treatment, patients with GBM typically have a dismal survival rate of only 12-16 months. Furthermore, many patients eventually experience tumor relapse. Proteins such as epigenetic modulators function to change how genes are activated in DNA without altering the genetic code. Inhibiting such epigenetic enzymes through chemical compounds has been shown to have anti-cancerous effect. The aim of this project is to find new compounds targeting epigenetic proteins effective against recurrent GBM and to identify how they work using lab-based methods. This project will address the urgent need of new treatment approaches for recurrent glioblastoma.

Faculty Supervisor:

Shraddha Pai

Student:

Partner:

Ontario Institute for Cancer Research

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Toronto

Program: